- Home
- PODD
PODD
Insulet Corporation
as 05-17-2024 4:00pm EST
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it worldwide.
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | ACTON |
| Market Cap: | 11.6B | IPO Year: | 2007 |
| Target Price: | $239.07 | AVG Volume (30 days): | 973.7K |
| Analyst Decision: | Buy | Number of Analysts: | 15 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 3.33 | EPS Growth: | 33200.00 |
| 52 Week Low/High: | $125.82 - $309.72 | Next Earning Date: | 05-09-2024 |
| Revenue: | $1,780,700,000 | Revenue Growth: | 30.17% |
| Revenue Growth (this year): | 17.91% | Revenue Growth (next year): | 18.54% |
Share on Social Networks:
Stock Insider Trading Activity of Insulet Corporation (PODD)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Petrovic Shacey | PODD | Director | Feb 28 '24 | Sell | $162.92 | 11,609 | $1,891,338.28 | 2,567 | SEC Form 4 |
| BORIO LUCIANA | PODD | Director | Dec 15 '23 | Sell | $207.08 | 72 | $14,909.76 | 2,278 | SEC Form 4 |
| Petrovic Shacey | PODD | Director | Nov 13 '23 | Sell | $165.02 | 2,075 | $342,416.50 | 41,130 | SEC Form 4 |
| Petrovic Shacey | PODD | Director | Nov 13 '23 | Sell | $165.02 | 12,925 | $2,132,883.50 | 0 | SEC Form 4 |
| Petrovic Shacey | PODD | Director | Nov 13 '23 | Sell | $164.33 | 20,000 | $3,286,600.00 | 2,567 | SEC Form 4 |
Latest Insulet Corporation News
PODD Breaking Stock News: Dive into PODD Ticker-Specific Updates for Smart Investing
MedTech Dive
2 days ago
Dexcom details plans for over-the-counter CGM as insulin pump firms seek Type 2 coverage
Benzinga
4 days ago
Will Insulet's Monopoly Crumble? Appellate Court Ruling Signals Shift in Automated Insulin Delivery Systems Market
Benzinga
4 days ago
Wall Street Trades Flat On Mixed Producer Inflation; Meme Stocks See Wild Ride, Bitcoin Drops: What's Driving Markets Tuesday?
MT Newswires
4 days ago
Insulet Shares Rise Despite Blue Orca's Short Position
Zacks
5 days ago
Insulet (PODD) Q1 Earnings Top, 2024 Revenue View Raised
Simply Wall St.
6 days ago
Results: Insulet Corporation Beat Earnings Expectations And Analysts Now Have New Forecasts
Insider Monkey
8 days ago
Insulet Corporation (NASDAQ:PODD) Q1 2024 Earnings Call Transcript
GuruFocus.com
8 days ago